Skip to content

Harrow HROW Return on equity

Return on equity at other companies

AbbVie logo
AbbVieABBV
89%+32.7pp
Bausch + Lomb logo
Bausch + LombBLCO
-3.4%-0.9pp
Ocular Therapeutix logo
Ocular TherapeutixOCUL
-68.6%+17.0pp
Viatris logo
ViatrisVTRS
-2%-0.9pp
Tarsus Pharmaceuticals, Inc. logo
Tarsus Pharmaceuticals, Inc.TARS
-14%-5.2pp
Kodiak Sciences Inc logo
Kodiak Sciences IncKOD
-208.8%+2,306pp

Other financials

Income statement

See full
Revenue$44.2M-7.6%
Gross profit$27.0M-16.3%
Operating income-$22.1M-96.6%
Net income-$27.6M-55.2%
EPS (diluted)-$0.74-48.0%

Balance sheet

See full
Cash & equivalents$94.6M+41.8%
Total debt$308.6M-32.9%
Total equity$28.7M-49.1%
Total assets$419.5M+15.2%

Cash flow

See full
Operating cash flow-$9.0M-146%
CapEx$194.0K+14.1%
Free cash flow-$9.2M-147%

Valuation

See full
Market cap$1.59B+38.4%
Enterprise value$1.81B+13.8%
P/S5.9×+0.5×

Profitability

See full
Gross margin74.1%-0.4pp
Operating margin7.3%+5.2pp
Net margin-19.8%+18.0pp
FCF margin5.7%+5.0pp

Returns & leverage

See full
Debt / equity10.7×+2.6×
Current ratio2.5×+1.6×

Where this comes from

Calculated from Harrow’s reported figures.

Based on trailing twelve months.

The official record: Harrow’s 10-Q, filed November 14, 2024, on SEC EDGAR. View the filing →

Ask your AI about Harrow's return on equity.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Harrow's return on equity?
Harrow (HROW) reported return on equity of -50% in Q3 2024.
How has Harrow's return on equity changed year-over-year?
Harrow's return on equity decreased by 26.0% year-over-year, from -39.7% to -50%.
What is the long-term trend for Harrow's return on equity?
Over 2 years (2021 to 2023), Harrow's return on equity has grown at a -27.2% compound annual growth rate (CAGR), from -93.6% to -49.6%.
What does return on equity mean?
Trailing-twelve-month net income divided by average shareholders' equity (average of the start and end of the trailing-twelve-month window). Measures the profit generated on each dollar of shareholder capital.